Clinical considerations of regenerative medicine in osteoporosis

Current Osteoporosis Reports

Volumn 12, Issue 2, 2014, Pages 230-234

  Ito, Hiromu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Mesenchymal stem cell; Osteoporosis; Regenerative medicine

Indexed keywords

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DENSITY; BONE MARROW; BONE REGENERATION; BONE REMODELING; BONE STRENGTH; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PERIOSTEUM; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; SKELETAL MUSCLE; TREATMENT PLANNING; AUTOTRANSPLANTATION; BONE DEVELOPMENT; MESENCHYMAL STROMA CELL; OSTEOPOROTIC FRACTURES; PROCEDURES;

BONE REGENERATION; CELL DIFFERENTIATION; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; REGENERATIVE MEDICINE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84904186675     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-014-0201-8     Document Type: Review

References (33)

1. • Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo). 2013;2013:125705. This paper reviews thoroughly osteoporosis and RANKL/OPG axis.
2. Todd CJ, Freeman CJ, Camilleri-Ferrante C, et al. Differences in mortality after fracture of hip: the East Anglian audit. BMJ. 1995;310(6984):904-8.
3. Prevention and management of osteoporosis. World Health Organization Technical Report Series, 2003; 921:1-164.
4. David C, Confavreux CB, Mehsen N, Paccou J, Leboime A, Legrand E. Severity of osteoporosis: what is the impact of comorbidities? Jt Bone Spine. 2010;77 Suppl 2:S103-6.
5. Katsara O, Mahaira LG, Iliopoulou EG, et al. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2011;20(9):1549-61.
6. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115-37. (Pubitemid 32275592)
7. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115(12):3318-25. (Pubitemid 43121814)
8. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-75. (Pubitemid 46797130)
9. Giampietro PF, McCarty C, Mukesh B, et al. The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: a pilot study utilizing the Marshfield Clinic Personalized Medicine Cohort. Osteoporos Int. 2010;21(3):467-77.
10. Urano T, Shiraki M, Ezura Y, et al. Association of a single-nucleotide polymorphism in low-density lipoprotein receptor-related protein 5 gene with bone mineral density. J Bone Miner Metab. 2004;22(4):341-5. (Pubitemid 38980950)
11. Turgeman G, Zilberman Y, Zhou S, et al. Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice. J Cell Biochem. 2002;86(3):461-74. (Pubitemid 36076164)
12. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154-6. (Pubitemid 11050741)
13. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-7. (Pubitemid 28516247)
14. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76. (Pubitemid 44233629)
15. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917-20.
16. •• Mikami Y, Matsumoto T, Kano K, Toriumi T, Somei M, Honda MJ, et al. Current status of drug therapies for osteoporosis and the search for stem cells adapted for bone regenerative medicine. Anat Sci Int. 2014;89(1):1-10. This is one of the few reviews to describe potential therapies for osteoporosis using stem cells.
17. • Ito H. Chemokines in mesenchymal stem cell therapy for bone repair: a novel concept of recruiting mesenchymal stem cells and the possible cell sources. Mod Rheumatol. 2011;21(2):113-21.
18. Tavassoli M, Crosby WH. Transplantation of marrow to extramedullary sites. Science. 1968;161(3836):54-6. This paper reviews the current knowledge of the migration of mesenchymal stem cells.
19. Jones E, McGonagle D. Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxford). 2008;47(2):126-31. (Pubitemid 351168218)
20. Gruber R, Mayer C, Bobacz K, Krauth MT, Graninger W, Luyten FP, et al. Effects of cartilage-derived morphogenetic proteins and osteogenic protein-1 on osteochondrogenic differentiation of periosteum-derived cells. Endocrinology. 2001;142(5):2087-94. (Pubitemid 32405968)
21. Farrington-Rock C, Crofts NJ, Doherty MJ, Ashton BA, Griffin-Jones C, Canfield AE. Chondrogenic and adipogenic potential of microvascular pericytes. Circulation. 2004;110(15): 2226-32. (Pubitemid 39372506)
22. Lee JY, Qu-Petersen Z, Cao B, et al. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol. 2000;150(5):1085-100.
23. Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, Robey PG. Circulating skeletal stem cells. J Cell Biol. 2001;153(5): 1133-40.
24. Chen HT, Lee MJ, Chen CH, et al. Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med. 2012;16(3):582-93.
25. Lavoie JF, Biernaskie JA, Chen Y, Bagli D, Alman B, Kaplan DR, et al. Skin-derived precursors differentiate into skeletogenic cell types and contribute to bone repair. Stem Cells Dev. 2009;18(6): 893-906.
26. Bi Y, Ehirchiou D, Kilts TM, et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med. 2007;13(10):1219-27. (Pubitemid 47530625)
27. Atesok K, Doral MN, Bilge O, Sekiya I. Synovial stem cells in musculoskeletal regeneration. J Am Acad Orthop Surg. 2013;21(4): 258-9.
28. •• Liu Y, Wu J, Zhu Y, Han J. Therapeutic application of mesenchymal stem cells in bone and joint diseases. Clin Exp Med. 2014;14(1): 13-24. This is one of the few reviews to describe potential therapies for osteoporosis using stem cells.
29. Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem. 1994;56(3):283-94. (Pubitemid 24360045)
30. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res. 1998;13(3):371-82. (Pubitemid 28146219)
31. •• Marie PJ. Targeting integrins to promote bone formation and repair. Nat Rev Endocrinol. 2013;9(5):288-95. This paper describes one of the potential strategies for treatment of osteoporosis using stem cells.
32. • Guan M, Yao W, Liu R, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med. 2012;18(3):456-62. This presents one of the potential strategies for treatment of osteoporosis using stem cells.
33. • Yao W, Guan M, Jia J, et al. Reversing bone loss by directing mesenchymal stem cells to bone. Stem Cells. 2013;31(9):2003-14. This paper presents one of the potential strategies for treatment of osteoporosis using stem cells.